Krystal Biotech buy The Goldman Sachs Group, Inc.
Start price
20.11.23
/
50%
€96.00
Target price
20.11.24
€146.38
Performance (%)
76.41%
End price
21.11.24
€169.35
Summary
This prediction ended on 21.11.24 with a price of €169.35. With a performance of 76.41% the BUY prediction by The_Goldman_Sachs_Gr was a big success. The_Goldman_Sachs_Gr has a follow-up prediction for Krystal Biotech where he still thinks Krystal Biotech is a Buy. The_Goldman_Sachs_Gr has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Krystal Biotech | 0.396% | 0.396% | 57.582% |
| iShares Core DAX® | 1,93 % | -2,11 % | 11,14 % |
| iShares Nasdaq 100 | -0,18 % | -5,90 % | -0,15 % |
| iShares Nikkei 225® | 7,08 % | 6,46 % | 28,83 % |
| iShares S&P 500 | -0,20 % | -3,67 % | -0,10 % |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Krystal Biotech diskutieren
Krystal Biotech, Inc. (NASDAQ: KRYS) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $160.00 price target on the stock.
Ratings data for KRYS provided by MarketBeat
In the thread Trading Krystal Biotech
Die von The_Goldman_Sachs_Gr gewählte maximale Laufzeit wurde überschritten